UCB and Amgen Abandon Trials for Fracture-Healing Drug


UCB and Amgenannounced today that they have halted trials for CDP7851/AMG785, or romosozumab, a fracture-healing drug. The news follows completion of the drug's phase 2 trials, but before phase 3 trials had commenced.

In a UCB statement, the company alludes to its most recent results and "general regulatory guidance" as the primary reasons for not pursuing additional testing. The company also states that safety concerns were not an issue and that its phase 2 trials won't affect continued testing on a similar drug to treat osteoporosis in post-menopausal women.

"Our sclerostin antibody project with Amgen is one of the most innovative pipeline programs in UCB's portfolio," UCB Chief Medical Officer Iris Loew-Friedrich said in a statement today. "We are very excited about the phase 3 program in PMO [post-menopausal osteoporosis] which is ongoing as planned and should provide first results at the end of 2015. Safety and other data collected so far indicate the potential for a change of treatment paradigms in postmenopausal osteoporosis."

UCB notes that the fracture-healing drug's phase 2 results will be presented at a future conference and that the decision to not pursue phase 3 trials has no impact on the company's 2012 financials. Shares of Amgen fell 1.6% today .

The article UCB and Amgen Abandon Trials for Fracture-Healing Drug originally appeared on Fool.com.

Fool contributor Justin Loiseau has no position in any stocks mentioned. You can follow him on Twitter, @TMFJLo, and on Motley Fool CAPS, @TMFJLo.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.